Case Study: A 44-Year-Old Galleria Executive’s Fat-Loss Protocol

Before anything else: the person in this article does not exist. "Marcus" is a composite — a fictional, illustrative 44-year-old executive assembled from patterns we see discussed across Houston telehealth practices, endocrinology clinics around the Texas Medical Center, and peptide-education communities. No detail here describes a specific patient, and nothing in this post is medical advice, a prescription, or an endorsement of any protocol for you. HTX Peptide does not sell peptides and does not provide sourcing guidance. This site is for adults 18 and older, and it exists to help you ask better questions of a licensed physician who actually knows your history. Read this as a worked example of how a careful, evidence-graded fat-loss conversation can unfold — not as a template to copy.

The Setup: A Galleria Corner Office and a Stubborn 30 Pounds

Marcus runs a mid-sized commercial real estate firm out of a tower near the Galleria. His days are a familiar Houston executive rhythm: 6 a.m. emails, back-to-back meetings, client dinners at steakhouses along Westheimer, and a standing weekend obligation to be visibly energetic for his two teenagers. Over roughly eight years he had gained about 32 pounds, most of it settling around his midsection. At 5'10" and 228 pounds, his body mass index sat just above 32, placing him in the range clinicians describe as obesity. His complaint was not vanity so much as fatigue, a creeping loss of stamina, and a family history of type 2 diabetes that his last physical had turned from an abstraction into a warning.

What made Marcus a useful illustration is that he arrived, as many Houston professionals do, having already read a great deal online. He had seen the social-media enthusiasm for GLP-1 medications, the bodybuilding-forum chatter about growth-hormone-releasing peptides, and the confident claims that a weekly injection could dissolve the weight without changing anything else. He wanted a shortcut. The value of his physician — and the point of this case study — was in slowing that impulse down and rebuilding it on evidence.

Why Screening Came First

No responsible fat-loss protocol begins with a molecule. It begins with a picture of the whole person. Marcus's physician ordered a comprehensive panel before discussing any specific compound: a metabolic panel, fasting glucose and hemoglobin A1c, a full lipid panel, liver and kidney function, thyroid studies including TSH and free T4, and a morning testosterone with the understanding that low energy and central weight gain can have hormonal contributors unrelated to peptides. Because a GLP-1 medication was on the table, the physician also reviewed personal and family history for medullary thyroid carcinoma and multiple endocrine neoplasia type 2 — both of which are contraindications carried in the boxed warning for GLP-1 and dual-agonist therapies — and screened for any history of pancreatitis.

Marcus's A1c came back at 5.9 percent, in the prediabetic range, which reframed the entire conversation. This was no longer only a cosmetic goal; it was a metabolic-risk goal, and that distinction matters both medically and, in Texas, often for what a physician can justify prescribing. His lipids were borderline, liver enzymes mildly elevated in a pattern consistent with fatty liver, and his testosterone was low-normal — enough to note and monitor, not enough to automatically treat. His thyroid was normal, which quietly ruled out one of the most common non-peptide explanations for stubborn weight.

Setting an Honest Goal

Marcus initially wanted to lose 40 pounds in three months for a family trip. His physician reframed the target around what the human trial data actually supports and what a body can safely shed. Landmark trials of tirzepatide, the dual GIP/GLP-1 receptor agonist, reported average total body weight reductions in the mid-teens to roughly 20 percent over 72 weeks at higher maintenance doses in people without diabetes — a genuinely large effect for a pharmacological agent, but one that unfolds over more than a year, not a season. A realistic first-quarter goal became 6 to 9 percent of body weight, paired with lab re-checks, rather than a number pulled from a countdown to vacation.

This reframing is where a lot of peptide enthusiasm quietly breaks down. The dramatic before-and-after stories that circulate online compress timelines and omit the resistance training, protein targets, sleep repair, and medical supervision that made those results durable and safe. An honest goal is not a smaller ambition; it is an ambition matched to evidence. Marcus's physician also made a point that reframed his motivation: the trip-driven deadline would be gone in three months, but the metabolic risk it obscured would still be his to manage for decades. Anchoring the goal to his A1c and his liver markers, rather than to a photograph, gave the plan a reason to continue after the vacation ended — which is precisely where most short-horizon efforts collapse.

Choosing the Anchor: Why Tirzepatide

With prediabetes on the chart, the physician anchored the plan around tirzepatide, which is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and separately approved for type 2 diabetes. It is not a peptide sold in the gray market in this scenario; it is a prescribed medication with a defined label, a known safety profile from large randomized trials, and — importantly for a case study on this site — the strongest human evidence base of anything Marcus considered. Reference maintenance dosing in the published trials escalated slowly over months, and the physician emphasized that the slow titration exists precisely to blunt the nausea, vomiting, and gastrointestinal effects that cause many people to quit.

We deliberately present no milligram schedule here as an instruction. The trials titrated upward in small increments across many weeks, and the appropriate dose for any individual depends on tolerance, response, kidney and liver function, and other medications — all of which live with the prescribing physician, not a blog. What matters conceptually is that tirzepatide was chosen as the evidence-graded anchor, and everything else in Marcus's plan was evaluated against the question: does this add value beyond the anchor, and is it worth the added uncertainty?

What Got Ruled Out, and Why

Marcus had read about a menu of other compounds and wanted them stacked on day one. His physician walked through each and, in this scenario, declined most. This section is the heart of the case study, because what a careful clinician removes is as instructive as what they keep.

The fat-targeting peptide fragments and "lipolytic" injectables that dominate forum discussions were set aside for a simple reason: the human evidence is thin to nonexistent, and none are FDA-approved for fat loss. Several exist only as research chemicals with no oversight of purity or dosing, and combining unknown-quality compounds with a potent prescribed agonist multiplies risk without a matching evidence payoff. The physician's stance was that an unproven addition has to clear a high bar when the anchor drug already carries the desired effect.

Tesamorelin — a growth-hormone-releasing hormone analog that is FDA-approved specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy — came up because Marcus's fat was central. But its approval is narrow, its studied population is specific, and using it off-label for general executive weight loss meant leaving the evidence base behind. It was noted as scientifically interesting and set aside as not indicated for his situation.

That left the growth-hormone-axis pairing Marcus was most curious about: ipamorelin, a selective growth-hormone secretagogue, and CJC-1295 without DAC, a growth-hormone-releasing hormone analog often discussed alongside it. Here the physician was candid in a way worth quoting in spirit: these are not FDA-approved for fat loss or for anti-aging, the human clinical data are limited and largely short-term, and much of what is claimed for them rests on mechanism, animal work, and anecdote rather than large controlled trials in people. They were framed strictly as research-purposes-only compounds that Marcus could explore later, with full informed consent, only if his physician judged it appropriate — and never as the engine of his fat loss.

The Reference-Range Protocol (Illustrative Only)

For transparency, here is the shape of what Marcus's supervised plan looked like — described as categories and reference ranges reported in literature and community protocols, never as milligram instructions and never as something to replicate on your own. The center of gravity was the prescribed tirzepatide, titrated slowly upward by his physician over months with the explicit goal of reaching an effective maintenance level while keeping gastrointestinal side effects tolerable. Blood work was scheduled at baseline, at roughly six weeks, and at three months.

1. Anchor: physician-prescribed tirzepatide, slow upward titration over months toward a tolerated maintenance dose, per label and clinical judgment.
2. Nutrition: a protein target near 1.6 grams per kilogram of goal body weight to protect lean mass during a caloric deficit, with the physician and a dietitian setting specifics.
3. Training: resistance training three to four times weekly, because GLP-1-class weight loss includes lean tissue unless muscle is actively defended.
4. Hydration and electrolytes: a deliberate Gulf-Coast-summer plan to offset reduced thirst and appetite from the medication.
5. Optional, deferred, research-only consideration: any growth-hormone-axis peptide discussion held for a later phase, contingent on physician judgment and full informed consent — not part of the initial fat-loss engine.

Notice what is doing the work in that list. Four of the five pillars are not peptides at all. The single prescribed medication provides appetite regulation and a metabolic assist, but protein, resistance training, hydration, and monitoring are what turn a number on a scale into a durable change in body composition and metabolic risk. This is the least glamorous and most important lesson of the entire case.

Monitoring: What the Labs and the Scale Actually Showed

By the six-week check, Marcus had lost about 11 pounds. His physician was more interested in the pattern than the number: appetite was down, evening grazing had nearly stopped, and his energy had improved once the initial nausea of dose escalation settled. The early gastrointestinal side effects — some nausea, a few days of reflux, mild constipation — were real but manageable, and consistent with what the trials report during titration. His hydration plan was adjusted after he admitted to skipping water on hot travel days.

At the three-month mark, the composite outcome looked like this: roughly 19 pounds down, about 8 percent of his starting weight, landing him near the conservative goal his physician had set rather than the aggressive one Marcus originally wanted. More meaningful than the scale, his A1c had drifted from 5.9 to 5.6 percent, moving him away from the diabetic threshold, and his liver enzymes and lipids had both improved. He had held most of his strength numbers in the gym, which suggested the lean-mass defense was working. None of this required a single non-FDA-approved peptide.

The Houston Context: Telehealth, Compounding, and the Local Reality

Marcus's experience is shaped by where he lives. Houston sits atop one of the densest medical ecosystems in the world — the Texas Medical Center — and the surrounding metro is thick with endocrinology practices, obesity-medicine specialists, and a fast-growing layer of telehealth providers advertising to professionals in the Galleria, The Woodlands, Sugar Land, Katy, Pearland, Clear Lake, Memorial, and the Heights. That access is a genuine advantage. It also means the market is noisy, and not every provider brings the same rigor to screening and monitoring.

Texas telehealth rules generally require a legitimate physician-patient relationship before a prescription, and much of the semaglutide and tirzepatide prescribed regionally has, at various points, moved through compounding pharmacies — an arrangement whose availability shifts with FDA shortage determinations and enforcement. The practical takeaway for a Houston reader is not a recommendation about any pharmacy or provider; it is a prompt to ask direct questions: Is this an FDA-approved product or a compounded version, and why? Who supervises my labs? What is the monitoring schedule? A provider who cannot answer those clearly is a provider to reconsider.

The heat deserves a final word because it is not a cliche here. A fat-loss protocol that suppresses appetite and thirst runs headlong into a climate that already stresses hydration and cardiovascular load for eight months of the year. Any Houston plan that ignores the Gulf-Coast summer is incomplete, and Marcus's physician treated hydration and heat-timing of workouts as clinical variables, not lifestyle garnish. In practice that meant moving his outdoor conditioning to early morning before the humidity peaked, keeping an electrolyte plan for travel days, and watching for the lightheadedness that can signal both dehydration and, occasionally, low blood sugar in someone eating far less than before. For an executive whose calendar rarely bends, building these guardrails into the protocol from day one mattered more than any willpower he could summon on a 100-degree August afternoon between meetings.

Lessons From a Composite

If Marcus were real, the honest summary of his first quarter would be unglamorous and encouraging at once. He did not dissolve 40 pounds in a season. He did lose roughly 8 percent of his body weight, nudge himself off the edge of diabetes, protect his strength, and — crucially — do it inside a monitored, evidence-graded framework where the most powerful intervention happened to be an FDA-approved medication, not a forum peptide. The compounds he was most excited about at the start were the ones his physician deferred or declined.

That inversion is the lesson. In a market that sells excitement, the durable results in this composite came from the boring, disciplined core: screen thoroughly, anchor on the strongest evidence, defend lean mass, monitor relentlessly, respect the climate, and treat every non-approved peptide as a research-purposes-only question to raise with a physician rather than an answer to buy. Your own physiology, history, and risks are yours alone, and only a licensed physician who examines you can decide what, if anything, is appropriate. This article is a map of how a good conversation can go — not a prescription, and not a promise.

Cross-reference the compound-specific guides on tirzepatide, ipamorelin, and CJC-1295 without DAC for the underlying evidence grades, and bring your questions — including the skeptical ones — to a qualified Houston clinician. The best outcome of reading a case study like this is not that you copy it, but that you walk into that appointment able to tell the difference between a claim backed by human trials and one backed by hope.